Dr Rasel Al-Amin
Rasel Al-Amin grew up in Bangladesh and just after his Bachelor’s Degree in Pharmacy from the University of Rajshahi, he was admitted to a master program at the Royal Institute of Technology (KTH), Stockholm and he moved in Sweden in September 2007. He received a Master of Science degree in Chemical Engineering. After a short research position at Karolinska Institute then he joined at the molecular tools research unit at Uppsala University in October 2011, where he later admitted for his PhD study and completed his PhD in Molecular Medicine in March 2019 under Prof. Ulf Landegren supervision. In early 2019 after his PhD defence, he was founded an entrepreneurial Swedish biotech start-up company ‘PharmaPrecision AB’ based on spatial in situ target-engagement technology together with his PhD mentor (Ulf Landegren) and others three high profile co-owners. His research work mainly focuse on molecular assays development in the field of drug discovery and precision proteomics. His expertises in oligonucleotide-based molecular assay development, biochemical and cellular methods for small molecular drug discovery and affinity-based proteomics. His research has resulted in highly cited publications in journals such Nature Methods, Nucleic Acids Research, Diabetologia, Analytical Chemistry and Communication Biology. His research has been attracted considerable interest within academia and industry. He has been selected and invited for presention at several top conferences around the world. He is also a former Thunberg Fellow at the Swedish Collegium for Advanced Study (SCAS). Rasel joined Tom’s group in 2023 and his research focuses on the development of therapeutic oligonucleotides that target mRNA.